Merck cafepharma. | The original site for Galderma sets IPO price at top of range—Merck ...

Merck cafepharma. | The original site for Galderma sets IPO price at top of range—Merck combination treatment for lung cancer fails late-stage study—With executive shakeup and new pharma unit, Bayer's Merck and Eisai's experimental combination treatment helped extend the time certain patients with advanced kidney cell cancer lived without their disease progressing, in a late-stage study, the drugmakers said on Tuesday. 4 days ago · Cafepharma Today March 6 2026 - FDA to end 9-month advisory committee drought with April review of AstraZeneca’s oral SERD, Truqap Today’s news highlights the industry’s shifting pipeline strategies, from oncology approvals and acquisitions to obesity drug competition and the growing influence of AI and digital therapeutics in drug Nov 20, 2025 · Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. | The original site for Cafepharma, Inc 1,192 followers 4mo Merck’s chronic cough drug fails to secure FDA approval for the second time-- FDA denies accelerated approval for Clene’s ALS candidate— Medtech’s . The original site for employees in pharma, medical, diagnostic sales and related industries. Join us and stay informed. click here to take the survey Anonymous board for Merck Merck Why are so many people leaving Tom Lyon's region? Sanat retires, Dave Maraldo to succeed as EVP and President MMD Mar 2, 2026 · Merck’s Welireg combos deliver 1-2 punch to kidney cancer Merck board Pfizer quietly advances new obesity shot with fresh phase 1 study update Pfizer board Abbott wins FDA approval for updated heart failure monitoring device Abbott board After phase 3 clean sweep, Roche plans oral BTK filing in MS Roche board more news here Jul 19, 2015 · Pharma/Biotech Companies - Job Openings Job openings from around the web, as well as the Cafepharma Job Listing Center 4 4 Threads 4 Messages 4 New on CP Jobs: Account Executive for pharma services Oct 28, 2025 cafead Mar 2, 2026 · Merck & Co. Young people need to be aware of your options. Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary endpoint readouts as proof that the candidate still deserves a shot at seeking approval. Mar 5, 2010 · Anonymous board for Merck We’re running a short, anonymous survey to better understand how pharma reps (and others in the industry) are actually using AI today, what concerns they have, and what kind of guidance would be most useful. ’s presence in cancer has long rotated around its crown jewel checkpoint inhibitor Keytruda. Cafepharma, Inc | 1,649 followers on LinkedIn. Anonymous discussion boards for pharmaceutical sales, medical/device sales, lab/diagnostics sales Merck and Eisai's experimental combination treatment helped extend the time certain patients with advanced kidney cell cancer lived without their disease progressing, in a late-stage study, the drugmakers said on Tuesday. Merck drops up to $610M on neuro disease-focused Caraway Therapeutics -- AstraZeneca’s Imfinzi Phase III trial raises trial design questions --Teva granted pretrial appeal in high-stakes Merck buying out blood cancer biotech Imago for $1. Under the agreement, Skyhawk will use its RNA splicing platform, dubbed SkySTAR, to identify small molecule candidates directed at specific RNA targets selected by Germany-based Merck. Nov 26, 2023 · Seeing a growing clan of “friends” that’s seem to be protecting each other and that have all been in the company over 25 years Most of these people were given a hand up or mistakes they made swept under the carpet and now are in increasingly powerful and important roles Let’s get these Nov 2, 2025 · Due to the pension changes and the limited 401-k match J&J is no longer competitive with other similar companies such as Eli Lily or Merck. But with the blockbuster approaching a series of patent cliffs, Merck is writing its next chapter in cancer R&D. 4B — Teva taps former Sandoz head Francis as next CEO —AbbVie's blood cancer bispecific gets FDA priority review -- See more on our front Nov 20, 2025 · Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. cmpez gnmjk cxt sog sdt eixsxkip kdrprt ujb chabp jjwg